Todd C. Brady is CEO & President at Aldeyra Therapeutics, Inc. (ALDX). They have made 11 open-market trades across 2 companies since 2014, most recently 2026-06-03.
CIK 0001579179
10 open-market purchases totalling $1.6M since 2014, against 1 sale. Across 10 scored buys the stock is down 9.8% at ninety days, and 10.3 points behind the S&P over the same stretch.
10 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| ALDX | 1,721,298 | $1.2M |
| SBPH | 60,016 | $290K |
| ONS | 153,288 | $99K |
| EVOK | 4,000 | $44K |
| Total | $1.6M |
Shares reported on the most recent Form 4, priced at the 2026-06-05 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 30% | 60% | 20% |
| Avg Move | -2.5% | +4.2% | -9.8% |
| Alpha | -0.7% | +3.5% | -10.3% |
| Scored | 10 | 10 | 10 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALDX | BUY | 2026-06-03 | 2026-06-05 | $1.67 | $418K | -1.9% | +22.3% | -20.1% |
| ALDX | SELL | 2024-03-11 | 2024-03-12 | $3.17 | $1.2M | -2.0% | +48.6% | +30.7% |
| ALDX | BUY | 2022-06-23 | 2022-06-27 | $3.36 | $59K | +13.7% | +27.8% | +34.7% |
| ALDX | BUY | 2019-12-16 | 2019-12-18 | $5.10 | $102K | +0.3% | +8.1% | -65.1% |
| ALDX | BUY | 2019-09-30 | 2019-10-02 | $5.68 | $49K | -5.9% | +7.3% | +6.2% |
| ALDX | BUY | 2019-09-23 | 2019-09-25 | $5.81 | $101K | -2.1% | +1.9% | -0.9% |
| ALDX | BUY | 2019-09-18 | 2019-09-20 | $5.91 | $169K | -9.8% | -3.3% | -4.1% |
| ALDX | BUY | 2019-09-13 | 2019-09-17 | $5.91 | $237K | -2.5% | +0.8% | -13.9% |
| ALDX | BUY | 2019-09-09 | 2019-09-11 | $5.14 | $103K | -2.0% | -14.5% | -15.7% |
| ALDX | BUY | 2017-02-17 | 2017-02-21 | $4.50 | $200K | +1.0% | -2.1% | -13.9% |
| EVOK | BUY | 2014-09-23 | 2014-09-24 | $5.70 | $23K | -20.8% | -0.3% | -0.3% |
| ALDX | BUY | 2014-05-07 | 2014-05-08 | $8.00 | $100K | -0.6% | +1.4% | +1.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.